For Generic Vancocin, An Advisory Committee Role Reversal
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will essentially play the part of a sponsor during the Aug. 4 pharmaceutical science panel meeting, arguing for favorable approval standards, while the brand sponsor, ViroPharma, will play the role of skeptic.
You may also be interested in...
Generic Vancocin Gets Clear Approval Path From Advisory Committee
Pharmaceutical science panel unanimously endorses FDA's proposed dissolution approach.
Generic Vancocin Gets Clear Approval Path From Advisory Committee
Pharmaceutical science panel unanimously endorses FDA's proposed dissolution approach.
ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
The biotech's HAE drug exceeded sales expectations during the second quarter, but FDA cites the company for misleading promotion.